S4 Medical Meets Primary Endpoint in Esophagus Deviation During Radiofrequency Ablation of Atrial Fibrillation (EASY AF Study)
CLEVELAND, Sept. 12, 2022 (GLOBE NEWSWIRE) -- S4 Medical Corp, an Ohio-based company with technology originating from The Ohio State University, announced that it is stopping the Esophagus Deviation During Radiofrequency Ablation of Atrial Fibrillation (EASY AF) Study due to successful achievement of the primary endpoint.
- CLEVELAND, Sept. 12, 2022 (GLOBE NEWSWIRE) -- S4 Medical Corp, an Ohio-based company with technology originating from The Ohio State University, announced that it is stopping the Esophagus Deviation During Radiofrequency Ablation of Atrial Fibrillation (EASY AF) Study due to successful achievement of the primary endpoint.
- "Completion of the IDE study and meeting our primary endpoint was a massive milestone for S4," says William Fuller, CEO and co-founder of S4 Medical.
- About S4 Medical Corp: S4 Medical Corp is a medical device company focused on innovative solutions for cardiac procedures.
- The company's initial product is a simple, yet comprehensive solution intended at reducing complications to the esophagus during catheter ablation treatment for atrial fibrillation.